RVU120 in Patients With Intermediate or High-risk, Primary or Secondary Myelofibrosis

NCT06397313 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

230

Enrollment

INDUSTRY

Sponsor class

Conditions

Myelofibrosis

Interventions

DRUG: RVU120
DRUG: Ruxolitinib

Sponsor

Ryvu Therapeutics SA